edoxaban

This page shows the latest edoxaban news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Xarelto no better than aspirin in secondary stroke study

Savaysa (edoxaban) some way behind in third and fourth place, respectively.
Xarelto beats aspirin for recurrent blood clots

edoxaban). Xarelto has slipped from a 60%-plus market share, however, with Eliquis gaining ground in part because of a debate about Xarelto's role in stroke prevention and the design
Portola rejection hands advantage to Boehringer's Pradaxa

Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. . ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.
Boehringer starts to feel impact of Spiriva generics

Squibb's Eliquis (apixaban) and Daiichi Sankyo's recently-approved Savaysa (edoxaban).
BMS claims 80% market share for Opdivo in US

and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery. ... Daiichi Sankyo is conducting a large, worldwide, phase III trial of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Add my company

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Success breeds success: This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change: ...
Investing in our People: As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....